Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03671889
NA

ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease

Sponsor: InSightec

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).

Official title: Assessment of Safety and Efficacy of ExAblate Blood-Brain Barrier Disruption for the Treatment of Patients With Probable Alzheimer's Disease

Key Details

Gender

All

Age Range

50 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2018-09-28

Completion Date

2030-01

Last Updated

2026-01-09

Healthy Volunteers

No

Interventions

DEVICE

Blood Brain Barrier (BBB) Disruption

Focal Ultrasound (FUS) involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct targets to induce BBB disruption.

Locations (10)

Delray Medical Center & Florida Atlantic University

Delray Beach, Florida, United States

Broward Health Medical Center & The University of Florida

Fort Lauderdale, Florida, United States

University of Florida Health Shands

Gainesville, Florida, United States

Baptist Health South Florida & Florida International University

Miami, Florida, United States

Advent Health

Orlando, Florida, United States

Tampa General Hospital

Tampa, Florida, United States

Weill Cornell Medicine

New York, New York, United States

The Ohio State University -Wexner Medical Center

Columbus, Ohio, United States

University of Texas Southwestern Medical Center

Dallas, Texas, United States

West Virginia University Rockefeller Neuroscience Center

Morgantown, West Virginia, United States